ALS2CR2 Antibody (C-term L289)
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, E |
---|---|
Primary Accession | Q9C0K7 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 47026 Da |
Antigen Region | 274-303 aa |
Gene ID | 55437 |
---|---|
Other Names | STE20-related kinase adapter protein beta, STRAD beta, Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 2 protein, CALS-21, ILP-interacting protein, Pseudokinase ALS2CR2, STRADB, ALS2CR2, ILPIP |
Target/Specificity | This ALS2CR2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 274-303 amino acids from the C-terminal region of human ALS2CR2. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | ALS2CR2 Antibody (C-term L289) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | STRADB |
---|---|
Synonyms | ALS2CR2, ILPIP |
Function | Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1. Adopts a closed conformation typical of active protein kinases and binds STK11/LKB1 as a pseudosubstrate, promoting conformational change of STK11/LKB1 in an active conformation (By similarity). |
Cellular Location | Nucleus. Cytoplasm |
Tissue Location | Highly expressed in heart, skeletal muscle, testis, liver and colon. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
ALS2CR2 potentiates the antiapoptotic activity of XIAP by enhancing XIAP-mediated activation of JNK1 (MAPK8) and other JNK family members, but not by modulating XIAP-mediated caspase inhibition. Expression of a catalytically inactive TAK1 (MAP3K7) mutant blocks the XIAP/ALS2CR2 activation of JNK1. In vivo coprecipitation experiments show that both ALS2CR2 and XIAP interact with TAK1 and TRAF6. It has been proposed that XIAP-mediated protection from apoptosis utilizes both a JNK1 activation pathway that involves ALS2CR2 and a caspase inhibition pathway that is independent of ALS2CR2.
References
Nishigaki, K., et al., J. Biol. Chem. 278(15):13520-13530 (2003).
Sanna, M.G., et al., J. Biol. Chem. 277(34):30454-30462 (2002).
Hadano, S., et al., Genomics 71(2):200-213 (2001).

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.